Dublin, April 21, 2021 (GLOBE NEWSWIRE) -- The "Hepatitis B Virus Infection - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
The global disease burden is high in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, Brazil, and China); it is especially high in China.
For most patients, CHB is a lifelong disease that cannot be cured, with only a very small number of patients entering remission each year. Patients with CHB have a 20% risk of developing life-threatening liver disease, such as cirrhosis and hepatocellular carcinoma (HCC) as a result of their condition. Guidelines by the American Association of the Study of Liver Diseases (AASLD) and the European Association for the Study of Liver (EASL) have recommended CHB to be treated with nucleotide analogs (NA).
Gilead Sciences and Bristol Myers Squibb (BMS) are the major players within the CHB market with their nucleotide analogs Viread (TDF, Gilead), Vemlidy (TAF, Gilead) and Baraclude (entecavir, BMS).
However, generic versions of TDF and entecavir dominate the 9MM. The CHB treatment pipeline is predominantly in early stages. Gilead's TLR-8 agonist selgantolimod, J&J's capsid assembly modulator JNJ-6379, and antisense nucleotide JNJ-3898 could significantly impact the CHB market across the 9MM. Also Replicor, Assembly Biosciences, and Ionis Pharmaceuticals are developing CHB therapies. A major unmet for CHB treatment remains the potential to achieve functional cure.
Key Highlights
- During the 10-year forecast period, there are six major pipeline products that are on track to launch, driving a forecast growth in the 9MM from $3.8B in 2019 to $5.2B in 2029, which represents a CAGR of 3.1%.
- To combat the unmet need of a functional cure, companies such as Gilead, J&J, Replicor, Ionis, and Assembly Biosciences are developing pipeline products with novel mechanism of action, with the potential of being used as a combination therapy either with current nucleotide analogs or with emerging products.
- The pipeline products are expected to launch in the second half of the forecast period in 2029. Antisense nucleotides are expected to gain a market share of 14.7% and sales of $761M in the 9MM by 2029. However, capsid assembly modulators from J&J and a toll-like receptor 8 agonist from Gilead are expected to compete with antisense nucleotides for market shares in the 9MM by the end of the forecast period.
Key Topics Covered:
1 Chronic Hepatitis B: Executive Summary
1.1 Chronic Hepatitis B Treatment to Experience Modest Market Growth over the Forecast Period from 2019-2029
1.2 Hepatitis B Therapies with Novel MOAs Will Supplement Existing NA Treatment
1.3 Pipeline Therapies with Novel MOAs Are Aiming to Increase CHB Cure Rates
1.4 Current CHB Treatment Pipeline Includes Agents with Novel MOAs
1.5 What Do Physicians Think?
2 Introduction
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.1 Sources
4.4.2 Forecast Assumptions and Methods
4.5 Epidemiological Forecast for CHB (2019-2029)
4.5.1 Diagnosed Prevalent Cases of CHB
4.5.2 Age-Specific Diagnosed Prevalent Cases of CHB
4.5.3 Sex-Specific Diagnosed Prevalent Cases of CHB
4.5.4 Diagnosed Prevalent Cases of CHB by HBeAg Status
4.5.5 Diagnosed Prevalent Cases of CHB by HBV DNA Level
4.5.6 Diagnosed Prevalent Cases of CHB by ALT Level
4.5.7 Diagnosed Prevalent Cases of CHB by Type of Liver Cirrhosis
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impacts
4.6.3 Limitations of Analysis
4.6.4 Strengths of Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.1.1 Treatment Guidelines and Leading Prescribed Drugs
5.1.2 Clinical Practice
5.2 KOL Insights on Disease Management
6 Competitive Assessment
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 The Need for a Functional Cure
7.3 Reduction in Drug Administration
7.4 Reduction in Treatment Time Frame
7.5 Discovery of Biomarkers
7.6 Improve Access to Diagnostics
8 R&D Strategies
8.1 Overview
8.1.1 R&D Strategy 1 - Mechanism of Action
8.1.2 R&D Strategy 2 - Combination Therapy
8.1.3 R&D Strategy 3 - Company Partnerships
8.2 Clinical Trials Design
8.2.1 Clinical Trials Design - Primary Endpoints
8.2.2 Clinical Trials Design - Combination Therapies
8.2.3 Clinical Trials Design - Focused on Phase II
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
11 Current and Future Players
11.1 Overview
11.2 Trends in Corporate Strategy
11.3 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers - Global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.4 Japan
12.5 Brazil
12.6 China
13 Appendix
Companies Mentioned
- Gilead Sciences
- Johnson & Johnson
- Assembly Biosciences
- Ionis Pharmaceuticals/GlaxoSmithKline
- Replicor
- HEC Pharma
- Ligand Pharmaceuticals
- Jiangsu Hansoh Pharmaceutical Group
- Bristol-Myers Squibb Co
- GlaxoSmithKline
- Merck & Co
- F. Hoffmann-La Roche
For more information about this report visit https://www.researchandmarkets.com/r/arv21g